NPC Comments on HHS Health Spending RFI

NPC submitted comments on the U.S. Department of Health & Human Services’ (HHS) request for information on its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

Read the Comments Now

Barriers to Paying for Value in Health Care

While other parts of the health care sector are moving
rapidly toward value-based arrangements, why are biopharmaceutical manufacturers and payers holding back?

Learn More About Regulatory Barriers in NPC's White Paper

Getting to the Roots of Health Care Spending

Learn More
Evidence icon

Evidence

How is high-quality, real-world evidence being generated, accepted and used to inform decision-making?
Value icon

Value

Is the value of medicines being recognized as an integral component of care?
Access icon

Access

What can we do to ensure patients have meaningful access to appropriate medications?
Innovation icon

Innovation

How can the health care system support biopharmaceutical innovation that improves patients’ lives?

Featured Content

Research

Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?

In an article published on the Health Affairs Blog, NPC and the Analysis Group conducted market research and found that although payers are thinking about how to cover gene therapies, more work is needed to fully address seven important coverage challenges.

Research

Communication

FDA Clarifies What Information Can Be Exchanged With Health Decision-Makers

The U.S. Food and Drug Administration took significant steps to modernize how health care information is communicated. The two final guidance documents address communications questions as well as many concerns raised by NPC through our longstanding research in this area and in public testimony and comments.

Communication

Events

NPC @ MedCity CONVERGE

Join NPC and health care stakeholders at MedCity CONVERGE in Philadelphia, Pennsylvania, on July 11-12 for a two-day summit on oncology innovation. NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, will address “Promising Drugs, Pricing and Access” in a panel discussion on Thursday, July 12, from 10:30 a.m.-11:45 a.m.

Events